Indoco Remedies Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/p4vrwv4szo5vm6ghxb7fwr9r.pdf

Key Takeaways


Domestic Business: Season Shift & Prescription Strategy

Aditi Panandikar: "we are ranked 20th among in the industry when it comes to the number of prescriptions we generate. And you'd be surprised that we are couple of ranks above Glenmark as well for the absolute number of prescriptions we generate. At the same time, we are ranked 30th when it comes to our achievement in rupee terms in the market."

Europe: Single-Product Destocking Shock

Sundeep Bambolkar: "One of our products which we supply to UK got heavily overstocked during COVID and the following years. And as a result, the orders for the last 3 months have been very, very minimum, practically zero, but the situation will improve from now onwards."

Margins: Remediation Costs & the 17% Question

Aditi Panandikar: "Agreed that in the first half and probably when we made the guidance or gave the guidance, the remedial cost and their impact may not have been fully understood, but every endeavor will be done for us to try and match the 17%."

US Business: Profit Share Visible but Opaque


Operational Initiatives & Capex


M&A: Scouting, Not Transacting

Aditi Panandikar: "in India, we've always been scouting for good brands. And internationally, we are keen to look at good facilities, but neither comes cheap and neither is available, to be honest."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic growthH2 must grow 14%–16% to hit full-year 11%–12% guided range; management confirmed confidenceFY24
Europe revenue₹375–380 crores, possibly betterFY24
EBITDA marginTry to match 17% guidance; remediation cost impact not fully understood when setFY24
Remediation cost impactExpected to persist for one more quarterQ3 FY24
US topline run rateConfident of continuing current run rate and even betterOngoing
US profit shareQ3 and Q4 profit share from Brinzolamide and other products sustainableH2 FY24
R&D spend5%–5.5% of revenueFY24
Debt repayment~₹24 crores in H2 FY24; ~₹45–₹50 crores annually for next two yearsFY24–FY26

Key Metrics

MetricQ2 FY24
Consolidated revenue₹465 cr, +15% YoY
Domestic formulation revenue₹228 cr, +9.4% YoY
International formulation revenue₹195 cr, +11.9% YoY
API revenue₹35.8 cr, +95.6% YoY
EBITDA₹72.4 cr, margin 15.6% vs 21.7% YoY
PAT₹32.9 cr, margin 7.1% vs 12% YoY
EPS₹3.60 vs ₹5.39 YoY
US business revenue₹81.4 cr, +17.5% YoY
Europe revenue₹63 cr, -15% YoY; overstocking at front-end partner impacted orders
Emerging markets revenue₹45.4 cr, +71.6% YoY
IPM rank and market share30th, 0.61% share (IQVIA Jul-Aug 23)
R&D spend guidance5%–5.5% of sales for FY24
FY24 EBITDA margin guidance17%; H1 at 14.6%, H2 would need ~20% (per an analyst's math)
Europe FY24 revenue guidance₹375–380 cr
Debt repayment H2 FY24~₹24 cr